Search Results

Japanese research team uses PET imaging to find tau protein pathology may be involved in onset of hallucinations and delusions in middle-aged and elderly

A research team comprising the National Institutes for Quantum Science and Technology (QST), Keio University, Kyoto University, Tokyo University of Science, and other institutions recently announced that researchers used PET imaging to observe tau protein pathology in the living brains of middle-aged and elderly psychiatric patients, and believe that such pathology may be related to psychiatric symptoms such as hallucinations and delusions that first appear after age 40. Proportion of positive tau PET and amyloid PET results Middle-aged and elderly psychosis generally refers to diseases in which psychiatric symptoms such as hallucinations and delusions first appear after age 40. Previous epidemiological studies and postmortem brain tissue studies have suggested that such symptoms may be related to neurodegenerative changes associated with dementia, but due to limited techniques for precise visualization and quantification of abnormal proteins in living brains, relevant evidence has long been insufficient.

2026-08-10

Low Danube Water Level Tests Bulgaria's Nuclear Operations, Energy Minister Says Kozloduy Plant Can Sustain Operations for About a Week and a Half

Bulgarian Energy Minister Iva Petrova said on August 7 that if the Danube River water level remains at its current level, the Kozloduy nuclear power plant can continue normal operations for about a week and a half. She described the situation facing the plant as difficult and dynamically changing, while emphasizing that the plant is currently operating stably with no direct failures affecting power generation. The Kozloduy nuclear power plant is a critical facility in Bulgaria's power system, and the high attention paid to Danube water level changes is mainly related to the cooling conditions required for plant operations. Persistently low water levels may increase operational dispatch pressure and require the energy sector to more frequently assess safety margins and subsequent response measures.

2026-08-08

PETRA III Synchrotron Radiation Study Reveals New Clues to Aging Mechanisms of the Uterine Broad Ligament

Austrian and German research teams recently used the PETRA III facility at the German Electron Synchrotron (DESY) to conduct X-ray analysis of the broad ligament, an important ligament supporting the uterus, providing new biomechanical clues for understanding the mechanisms of pelvic organ prolapse. The findings were published in *Acta Biomaterialia*. Pelvic organ prolapse is a common but poorly understood issue in women's health, affecting approximately 40% of women, and predominantly occurring in the latter half of life. Medical researchers have previously speculated that age-related loosening of the ligaments surrounding the uterus may be a significant contributing factor to prolapse. The broad ligament connects the uterus to the pelvic wall, and its strength and elasticity primarily derive from collagen...

2026-08-09

China's First Homegrown Radiopharmaceutical Receives Dual FDA Breakthrough Therapy and Fast Track Designations

On August 6, Nuoyu Medical announced that the U.S. Food and Drug Administration (FDA) has officially granted Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) to the company's independently developed 68Ga-NYM096. This marks the first product in China's original radiopharmaceutical field to receive FDA Breakthrough Therapy Designation, and the first to receive both FDA Breakthrough Therapy and Fast Track designations simultaneously, creating a milestone breakthrough in the radiopharmaceutical field. 68Ga-NYM096 is a small-molecule diagnostic radiopharmaceutical for renal cancer that specifically binds to CAIX, suitable for positron emission tomography (PET) imaging of suspected or confirmed metastatic clear cell renal cell carcinoma (c...

2026-08-08

Professor Lin Guoxian from the BC Cancer Agency Delivers Academic Exchange at the Institute of Radiation Medicine, Chinese Academy of Medical Sciences

Lin Guoxian: Professor at the BC Cancer Agency, whose research focuses on the development of targeted radiopharmaceuticals for the diagnosis and treatment of various tumors. To date, he has led/participated in the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed the clinical translation of 7 self-developed radiopharmaceuticals for the diagnosis and treatment of multiple tumor types. During the seminar, Professor Lin Guoxian, based on his team's years of frontier exploration, systematically reviewed the research progress of nuclear drugs targeting PSMA for prostate cancer: first, the molecular design and clinical advantages of F-18 labeled PSMA-targeted PET imaging agents; second, the substantial improvement of tumor targeting of Lu-177 labeled therapeutic radiopharmaceuticals through rational optimization of molecular structures,...

2026-08-07

Institute of Radiation Medicine, Chinese Academy of Medical Sciences Hosts Academic Seminar on PSMA-Targeted Radiopharmaceuticals

On August 3, the Institute of Radiation Medicine, Chinese Academy of Medical Sciences held an academic seminar, inviting Professor Lin Guoxian from the BC Cancer Agency in Vancouver, Canada, to deliver a lecture titled "Development of Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals for the Diagnosis and Treatment of Prostate Cancer." The seminar was held in a hybrid format, with some researchers and graduate students from the institute attending in person. Professor Lin Guoxian has long been engaged in the development of targeted radiopharmaceuticals for cancer diagnosis and therapy, having led or contributed to the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed clinical translation of 7 self-developed radiopharmaceuticals applied in...

2026-08-07

First Validation of Novel PRI Technology: Existing PET Tracers Can Image Tissue Microenvironment

August 6, 2026 - A joint research team from the Graduate School of Engineering at the University of Tokyo and the University of York in the UK announced that they have established a novel geometric imaging principle utilizing positron three-photon decay and successfully validated Positronium Ratio Imaging (PRI) technology for the first time. This method can be used in conjunction with existing clinical PET tracers and is expected to provide a new means of observing tissue microenvironments in nuclear medicine imaging. Conceptual diagram of next-generation nuclear medicine imaging utilizing positron-3-photon decay. Current clinical PET scans primarily rely on the positron two-photon annihilation process to visualize the distribution and accumulation of tracers in the body, but they provide limited information on microenvironmental factors such as tissue hypoxia that are associated with disease malignancy...

2026-08-07

Petrovietnam Calls for Synchronized Regulation and Development in Ninh Thuan 2 Nuclear Power Project

Petrovietnam has proposed adopting a synchronized coordination mechanism in the development of the Ninh Thuan 2 nuclear power project. The Group believes that for this nuclear power plant project, regulatory, licensing, and inspection procedures should proceed in parallel with the project development process during the investment preparation phase. This approach can enhance document quality, control risks, and ensure the project is implemented safely and in compliance with standards. Petrovietnam emphasized that nuclear power projects require regulatory work (including licensing, assessment, and review) to be integrated into all stages of the project lifecycle, rather than being treated as a subsequent step. The Vietnam Oil and Gas Group proposed that, to effectively advance project preparation, regulatory capacity building should be strengthened...

2026-08-06

Japanese PET Study Suggests Late-Onset Psychosis May Be Linked to Neurodegenerative Pathology

A nuclear medicine imaging study conducted by a Japanese research team has shown that many adults who experience psychotic symptoms such as hallucinations and delusions for the first time after age 40 have abnormal protein deposits in the brain associated with Alzheimer's disease and other neurodegenerative disorders. The study included 37 patients with late-onset psychosis and 47 age-matched healthy controls. The researchers used the amyloid PET tracer ^11C-PiB and the tau protein PET tracer ^18F-florzolotau to assess the accumulation of β-amyloid and tau proteins in the participants' brains. The results showed that among patients with late-onset psychosis, β-amyloid positivity...

2026-08-06

CNNC & CIR Co-sponsors Regional Nuclear Medicine Department Development Training Program (Ganzhou Session) and Ganzhou Cancer Hospital High-Quality Nuclear Medicine Diagnosis and Treatment Project Launched Simultaneously

Recently, the Regional Nuclear Medicine Department Development Training Program (Ganzhou Session) and the Ganzhou Cancer Hospital High-Quality Nuclear Medicine Diagnosis and Treatment Project were launched simultaneously at Ganzhou Cancer Hospital. An expert panel from the Nuclear Medicine Branch of the Chinese Medical Association, along with representatives from CNNC & CIR and Atom High-Tech, visited the hospital for research and exchange. More than 200 medical staff from medical institutions at various levels across Jiangxi Province attended the event. The launch ceremony was moderated by Yang Chuansheng, Director of the Nuclear Medicine Department at Ganzhou Cancer Hospital. Fu Wei, Deputy Director of the Ganzhou Municipal Health Commission; Wang Jing, Chair of the Nuclear Medicine Branch of the Chinese Medical Association; and Huang Xingwei, Party Secretary of Ganzhou Cancer Hospital, attended and delivered speeches. Wang Jing stated that nuclear medicine plays a vital supporting role in the precise diagnosis and treatment of major diseases such as cancer, and that promoting the standardized development of regional nuclear medicine at the city and county levels is conducive to channeling high-quality medical resources to the grassroots and enhancing primary healthcare service capabilities.

2026-08-06

US Intermountain Health Opens New Outpatient Clinic in Las Vegas, Equipped with PET/CT and Linear Accelerator

Intermountain Health, headquartered in Salt Lake City, recently opened a new outpatient clinic in southwest Las Vegas. Named Badura Clinic, the facility spans approximately 90,000 square feet and is located in the Spring Valley area, marking the health system's first new construction project in Nevada. The three-story Badura Clinic officially opened following a ribbon-cutting ceremony and community open house on July 30. The clinic consolidates primary care and select specialty services previously dispersed across multiple locations in the Las Vegas Valley, offering more centralized medical care for children, adults, and senior patients. According to the introduction, the clinic's services include adult and...

2026-08-05

ASP Isotopes PET Lab Revenue Grows Over 50% in First Half of Year, Isotope Enrichment Facilities Advance Toward Commercial Production

ASP Isotopes Inc. recently released a letter to shareholders outlining operational progress across its business segments ahead of the company's second-quarter 2026 financial results announcement. The company stated that its PET lab segment achieved organic revenue growth of more than 50% in the first half of 2026 compared to the same period in 2025. Based on current expectations, the segment's full-year 2026 revenue is projected to be approximately $14 million, up from $6 million in 2025. PET-related operations are typically closely associated with radiopharmaceutical preparation, molecular imaging, and nuclear medicine diagnostic applications. On the isotope front, ASP Isotopes stated that its silicon-28 and ytterbium-176 enrichment facilities have entered the final stage before commercial production, with first deliveries expected in the second half of 2026...

2026-08-05

Curium and Lantheus Reach Definitive Merger Agreement to Build a Global Integrated Radiopharmaceutical Theranostics Platform

On August 3, global radiopharmaceutical company Curium announced that it has entered into a definitive merger agreement with Lantheus Holdings, Inc. Under the agreement, Curium US Holdings LLC will merge with Lantheus through its wholly owned subsidiary, with a total consideration of up to $114.50 per share and a total transaction value of approximately $8 billion. Under the terms of the agreement, Curium US will acquire all outstanding shares of Lantheus at $102.50 per share in cash upon closing of the transaction. In addition, Lantheus shareholders will receive non-transferable contingent value rights, entitling them to up to $12.00 per share in additional cash payments if certain commercial milestones for Lantheus-related products are achieved by 2030...

2026-08-04

DuChemBio Completes Supply Chain for Prostate Cancer Radiopharmaceutical

DuChemBio, a Korean radiopharmaceutical company, announced on August 4 that it has completed the supply chain for ProstaSeek (active ingredient: 18F-plotupolastat), a radiopharmaceutical for prostate cancer diagnosis, in the Yeongnam and Honam regions. The drug targets prostate-specific membrane antigen (PSMA), and all tertiary general hospitals in both regions that perform PET-CT scans and provide prostate cancer diagnosis and treatment have been included in its supply scope. According to data from the National Cancer Registry of the Korean Ministry of Health and Welfare, new prostate cancer cases reached 22,640 in 2023, accounting for 7.8% of all cancer cases and ranking sixth in male cancer incidence; with the increasing adoption of PSMA-targeted therapy, the demand for precise diagnosis before prostate cancer treatment is also growing rapidly.

2026-08-04

United Imaging Healthcare's New-Generation Digital PET/CT "uMI Panvivo" Enters Clinical Use in Japan

August 3 news, United Imaging Healthcare Japan Co., Ltd. announced that the first unit in Japan of its new-generation digital PET/CT scanner uMI Panvivo has been put into clinical use at Saitama Central Clinic, located in Omiya-ku, Saitama City. Saitama Central Clinic is a medical institution specializing in diagnostic imaging. Since its opening in 2009, the clinic has continuously conducted comprehensive cancer screening centered on PET/CT scans, and provides FDG-PET cancer examination services based on the needs of local medical institutions, with an annual PET/CT examination volume ranking among the highest in Japan. With the introduction of uMI Panvivo, the clinic expects to further shorten examination time and enhance image quality on the basis of its existing high-precision diagnostic imaging...

2026-08-03